30
Participants
Start Date
July 27, 2025
Primary Completion Date
March 1, 2027
Study Completion Date
March 1, 2028
Allogenic CD19-CAR-γδT cell
Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6× 10\^6 cells/kg); Phase 2 : dose of RP2D.
Fludarabine
"Intravenous fludarabine 30\~50 mg/m\^2/day on days~-5, -4, and -3."
Cyclophosphamide
Intravenous cyclophosphamide 500\~1000 mg/m\^2/ day on days -5, -4, and -3.
RECRUITING
Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing
Chinese PLA General Hospital
OTHER